Roclanda (latanoprost / netarsudil)
- Region
- 🇪🇺 EU
- Active substance
- latanoprost / netarsudil
- Company
- Santen Oy
- Status
- Authorised
- Therapeutic area
- Glaucoma, Open-Angle; Ocular Hypertension
- CHMP opinion
- Thu 12 Nov 2020
- EU approval
- Thu 07 Jan 2021
- Application
- EMEA/H/C/005107
- ATC
- S01EE
- Official record
- www.ema.europa.eu
Indication
Roclanda is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.
Regulatory milestones
No milestones recorded in the last year.
Follow Roclanda
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.